SCHEMBL2711280

SCHEMBL2711280

N#CC(=Cc1cccnc1)c1c[nH]c2ccc(O)cc12

nearest known ligand 0.78

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 10/20 0.78
CLK1 P49759 9/20 0.78
KIF20A O95235 10/20 0.74
CLK2 P49760 2/20 0.64
CLK4 Q9HAZ1 2/20 0.64
DYRK1B Q9Y463 2/20 0.64
CDK5 Q00535 1/20 0.64
CDK5R1 Q15078 1/20 0.64
PIP4K2A P48426 1/20 0.49
MAPT P10636 3/20 0.48
KDM4E B2RXH2 2/20 0.48
ALDH1A1 P00352 2/20 0.48
KMT2A Q03164 2/20 0.48
MEN1 O00255 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
MAPK1 P28482 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30937474 1.00 DYRK1A (0.78) DYRK1ACLK1KIF20ACLK2CLK4
SCHEMBL2711278 1.00 DYRK1A (0.78) DYRK1ACLK1KIF20ACLK2CLK4
SCHEMBL19192706 0.88 DYRK1A (0.60) DYRK1ACLK1KIF20ACLK2CLK4
SCHEMBL19192548 0.87 DYRK1A (0.76) DYRK1ACLK1KIF20ACLK2CLK4
SCHEMBL2725098 0.87 DYRK1A (0.76) DYRK1ACLK1KIF20ACLK2CLK4
SCHEMBL2725265 0.87 DYRK1A (0.76) DYRK1ACLK1KIF20ACLK2CLK4
SCHEMBL2726304 0.87 DYRK1A (1.00) DYRK1ACLK1KIF20ACLK2CLK4
SCHEMBL2726290 0.87 DYRK1A (1.00) DYRK1ACLK1KIF20ACLK2CLK4
SCHEMBL2725264 0.87 DYRK1A (0.76) DYRK1ACLK1KIF20ACLK2CLK4
SCHEMBL2726292 0.87 DYRK1A (1.00) DYRK1ACLK1KIF20ACLK2CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10624876-B2 Derivatives of indole for the treatment of endometriosis BIOKINESIS (FR) 2020-04-21 US claimed
US-20190275000-A1 NEW DERIVATIVES OF INDOLE FOR THE TREATMENT OF ENDOMETRIOSIS DIACCURATE (FR) 2019-09-12 US claimed
EP-3529243-A1 NEW DERIVATIVES OF INDOLE FOR THE TREATMENT OF ENDOMETRIOSIS Biokinesis (FR) 2019-08-28 EP claimed
WO-2018077795-A1 NEW DERIVATIVES OF INDOLE FOR THE TREATMENT OF ENDOMETRIOSIS BIOKINESIS (FR) 2018-05-03 WO claimed
US-9212138-B2 Use of derivatives of indoles for the treatment of cancer COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2015-12-15 US claimed
US-20140235654-A1 USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2014-08-21 US claimed
US-8703808-B2 Use of derivatives of indoles for the treatment of cancer CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2014-04-22 US claimed
US-20130131084-A1 USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-05-23 US claimed
EP-2445497-A2 USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER Centre National de la Recherche Scientifique (FR) 2012-05-02 EP claimed
WO-2010150211-A2 USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2010-12-29 WO claimed
US-10624876-B2 Derivatives of indole for the treatment of endometriosis BIOKINESIS (FR) 2020-04-21 US disclosed
US-20190275000-A1 NEW DERIVATIVES OF INDOLE FOR THE TREATMENT OF ENDOMETRIOSIS DIACCURATE (FR) 2019-09-12 US disclosed
EP-2445497-B1 Use of derivatives of indoles for the treatment of cancer CENTRE NAT DE LA RECH SCIENT (C N R S ) (FR) 2017-08-02 EP disclosed
US-9212138-B2 Use of derivatives of indoles for the treatment of cancer COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2015-12-15 US disclosed
US-20140235654-A1 USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2014-08-21 US disclosed
US-8703808-B2 Use of derivatives of indoles for the treatment of cancer CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2014-04-22 US disclosed
US-20130131084-A1 USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-05-23 US disclosed
EP-2445497-A2 USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER Centre National de la Recherche Scientifique (FR) 2012-05-02 EP disclosed
WO-2010150211-A2 USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2010-12-29 WO disclosed
EP-2266562-A1 Use of derivatives of indoles for the treatment of cancer Centre National de la Recherche Scientifique (FR) 2010-12-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140235654-A1 USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER IDO1, IDO2, INMT DYRK1A 597/4885CLK1 3098/4885KIF20A 871/4885
US-20190275000-A1 NEW DERIVATIVES OF INDOLE FOR THE TREATMENT OF ENDOMETRIOSIS IDO1, IDO2, CYP19A1 DYRK1A 802/4885CLK1 3902/4885KIF20A 2234/4885
US-10624876-B2 Derivatives of indole for the treatment of endometriosis IDO1, IDO2, CYP19A1 DYRK1A 1084/4885CLK1 3666/4885KIF20A 2497/4885
US-20130131084-A1 USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER IDO1, IDO2, INMT DYRK1A 597/4885CLK1 3098/4885KIF20A 871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.